Necrotizing small intestine colitis (NEC) treatment: Human placental extract Protego-PD?

Plakous Pharmaceuticals Has announced that its human placenta extract Protego-PD ™, whichprevention of necrotizing small intestine colitis (NEC) in premature, has been awarded the orphan drug title by theFDAProtego-PD ™ is an oral cellless biotherapeutic drug extracted from the human placentaRobert Boyce, chief executive of Plakous Therapeutics, said: "As there is no approved NEC treatment, the Protego-PD ™ is an important step in stopping this devastating disease."necrotizing small intestine colitis (NEC) is a disease that is more common in premature babies and can cause small intestine necrosis, which can be life-threatening in severe conditionMore than 90% of NEC cases occur in very low-weight infants (VLBWB), and the earlier the birth, the easier it is to get NECInitial symptoms of NEC include feeding intolerance, increased stomach residue, bloating, and supaurateSymptoms can rapidly worsen to perforation of the small intestine, peritonitis and low blood pressure, and abdominal discolorationNEC is a rare pediatric disease that affects about 6,000 very low-weight infants (VLBWB) in the United States each year, with a mortality rate of 30%, and no approved NEC treatment